Six prophylaxis agents, five of them clustered near the top of the same efficacy band. Where efficacy converges, positioning has to be argued somewhere else.
Prophylaxis in hereditary angioedema has become a crowded field in which comparative efficacy no longer separates the leading agents. Positioning therefore starts from the contested cohort rather than from a head-to-head claim: which patients are not yet on prophylaxis at all, which are on an agent that does not suit their route or dosing preference, and which are managed on demand.
The unit of value is the avoided attack, and above all the laryngeal attack that drives mortality and emergency cost. Building the case on list price against list price concedes the argument before it starts; converting trial attack-rate reductions into attacks averted, and attacks averted into avoided acute care, is what makes a value story hold with a payer who is already paying for an incumbent.
Two conversions run in parallel and have to be modelled separately. The first moves attack-active patients off on-demand-only management onto any prophylaxis, which is the larger opportunity in markets where on-demand therapy still dominates, including much of the Gulf. The second is the switch onto an oral agent from an injectable, which is a different decision, made by different patients, on different grounds. Treating them as one number produces a forecast that is wrong in both directions.
AXLRx hereditary angioedema reports isolate the never-prophylaxed cohort across the US, UK and Gulf, value agents on attacks averted, and model the two conversions independently.
The prophylaxis class is fracturing along route: oral berotralstat and the first oral on-demand agent against a still-injectable antibody field.
Specialty-tier prior authorization, prophylaxis above $300K/patient/yr, ICER 2018/2021 value-based benchmarks and no-concurrent-acute-agent rules.
HAE pathophysiology, the Type I/II split, attack burden and the diagnostic-delay problem that defines the US in-market landscape.
GCC HAE management is acute-only, with prophylaxis penetration near zero. More than 85% of patients are undiagnosed, and NPHC coverage for lanadelumab would be the access trigger for the region's largest market.
An estimated 8,000-9,000 Americans have HAE, and only 35-40% receive any prophylaxis. That leaves 2,500-4,000 attack-eligible patients never treated, a pool nearly as large as the entire treated population.
A 37-centre national survey confirms 1,152 UK HAE type I/II patients. A top-down 1:32,000 prevalence rate implies roughly 2,000, and the UK HAE Alliance's broader planning estimate runs to 5,000-6,000, of which only 1,500-2,000 are on prophylaxis today.
GCC HAE access is structurally two-tier: broad acute coverage, but a prophylaxis bar few clear. Only 30-40% of applicants clear NPHC's individual-case prophylaxis review, and private insurance beats the NPHC pathway on speed.
Binding constraint: grow the never-prophylaxed cohort before donidalorsen resets the oral efficacy bar — not switch stable lanadelumab patients.
UK HAE Alliance genetic testing, an 87% attack-rate reduction on lanadelumab, and the NICE TA606 prophylaxis standard defining NHS management.
An estimated 8,000-9,000 Americans live with hereditary angioedema. Just 35-40% receive any prophylaxis, leaving 2,500-4,000 patients who meet treatment criteria untreated, the funnel this model sizes precisely.
England's NICE has issued three positive technology appraisals funding HAE prophylaxis since 2019 (TA606, TA738, TA1101). The two newest MHRA-licensed agents, donidalorsen and sebetralstat, remain in NICE appraisal with no confirmed final NHS funding decision.
Epidemiology projects 1,200-1,500 GCC HAE patients; the GCC allergy society's own case registry counts only 400-600. The gap is not a contradiction, it is the diagnostic-capacity constraint of just 6-10 specialist physicians across all six states.
KFSH&RC, AUH, and Hamad Medical Corporation anchor a GCC HAE specialist community that SACIA sizes at just 6-10 physicians regionwide. That concentration is exactly what this workbook sizes before any individual name enters it.
Lanadelumab lists near $450,000 a year against berotralstat's roughly $95,000. ICER's 2021 fair-value benchmark for berotralstat lands almost exactly on that list price, and the three 2025 entrants carry no ICER anchor of their own.
HAE family cascade screening opportunity, laryngeal attack burden, and the prophylactic therapy access gap across GCC specialist centres.
Lanadelumab tenders at SAR 300,000-400,000 a year, but NPHC has no routine formulary price at all. Access runs through an individual-case bar only 30-40% of submissions clear, while private VHI approves at a materially lower documentation threshold.
Epidemiology implies 1,200-1,500 true GCC HAE patients, but the KFSH&RC registry confirms fewer than 200. A separate planning estimate used for launch work lands at 400-600 — three numbers, one diagnostic-capacity story.
NICE TA606 commissioned lanadelumab with a PAS and 87.5% real-world attack reduction. Berotralstat's TA738 recommendation is now tested against that same benchmark.
Three completed NICE standard technology appraisals already fund HAE prophylaxis in England (TA606, TA738, TA1101). Every one cleared at the ordinary £20,000 to £30,000 per QALY bar and is held behind a confidential Patient Access Scheme, so a new entrant inherits a comparator-dense field in which garadacimab's £20,625 list pen is the only transparent price.
HAE prophylaxis barely exists as a category in the GCC. Under 15% of patients are on any prophylaxis versus 35-40% in the US, making this category creation, not competitive share capture.
The UK HAE Alliance counts 5,000-6,000 total patients, of whom 1,500-2,000 are on NICE-commissioned prophylaxis. A further 1,500-2,500 are attack-active but never treated, and Longhurst et al.'s 37-centre registry confirms 1,152 patients from the bottom up.
Five NHS specialist centres manage more than 90% of UK HAE patients. Sheffield, Cambridge, Birmingham, Guy's and St Thomas', and Manchester. That concentration is what this workbook sizes before any physician enters the K1-K6 gate structure.
Three NICE technology appraisals (TA606, TA738, TA1101) each carry a confidential Patient Access Scheme. Garadacimab's published £20,625 per-pen price is the only fully transparent figure in the class, and two MHRA-licensed agents still have no NICE-confirmed net price.
Lanadelumab leaves the never-prophylaxed UK HAE population open. This sizes the PAS discount needed to clear NICE's standard TA bar, and the donidalorsen clock a fast-moving competitor is running against you.
Hereditary angioedema runs near 1 in 50,000, implying roughly 8,000 to 9,000 US patients, about 85% Type I C1-INH deficiency and 15% Type II. Diagnosed and engaged patients span only 6,000 to 10,000 on HAE Association survey data. The gap widens abroad: a 2023 survey confirms 1,152 UK Type I/II patients across 37 specialist centres against a 5,000 to 6,000 planning estimate, and the GCC confirms fewer than 200 against an implied 1,200 to 1,500. Identification, not prevalence, is the whole commercial story.
Confirmation rests on a low C4 screen, then C1-INH antigenic and functional testing, with SERPING1 sequencing for ambiguous cases. Assay availability is not the obstacle; recognition is. Attacks are misread as ordinary allergic angioedema or abdominal emergencies, producing a mean 8 to 10 year delay that stretches to 12 to 15 years in the GCC. Family cascade screening is the fastest yield, averaging 3.8 relatives per index case in the KFSH&RC registry, yet it stays near-absent where only six to ten specialists cover a region.
Prophylaxis splits by route. Injectable antibodies lead on magnitude: lanadelumab (Takhzyro, Takeda, 2018, HELP ~87%), garadacimab (Andembry, CSL, 2025, VANGUARD ~87%) and donidalorsen (Dawnzera, Ionis, 2025, OASIS-HAE 81%), alongside subcutaneous C1-inhibitor Haegarda (CSL Behring, 2017). Oral berotralstat (Orladeyo, BioCryst, 2020) trades magnitude for convenience at ~44%. On-demand covers oral sebetralstat (Ekterly, KalVista, 2025, 1.6-hour median relief) and the older bradykinin-B2 antagonist icatibant (Firazyr, 2011). Route and dosing, not efficacy ceiling, now separate the field.
Start from diagnosed patients, not epidemiology, then stratify by attack rate. AXLRx builds the funnel from the 6,000 to 10,000 diagnosed US patients down to the 35 to 40% currently prophylaxed, isolating the 2,500 to 4,000 attack-active but never-prophylaxed cohort defined by the three-attacks-per-year or laryngeal-history bar that payers actually apply. A separate 1,000 to 1,500 FXII-HAE and normal-C1-INH subpopulation is carved out because kallikrein-targeted agents serve it less predictably. Each geography inherits its own eligibility gate: the GCC's six-attack NPHC documentation threshold shrinks the pool far below the US line, so the treat-eligible number is a payer construct as much as a clinical one.
Two conversions run in parallel and must be modelled separately. The first moves attack-active patients off on-demand-only management, where C1-inhibitor and icatibant dominate the GCC, onto any prophylaxis; the second moves prophylaxed patients from injectables onto oral agents. AXLRx sizes each with distinct conversion rates, since the never-prophylaxed patient is won on category creation while the injectable-to-oral switch is won on route preference against a stable lanadelumab base holding roughly 45% share. Attacks-averted, acute-therapy offset and administration burden feed the model, and the oral-conversion curve is anchored to berotralstat's observed ~20% uptake rather than a blank-slate assumption.
The unit of value is the avoided attack, above all the laryngeal one that drives mortality and emergency cost. AXLRx converts trial attack-rate reductions, ~87% for lanadelumab and garadacimab, 81% for donidalorsen, ~44% for oral berotralstat, into attacks averted per patient-year, then nets acute-therapy and hospitalisation savings against the $300,000-plus US prophylaxis cost. The result is benchmarked to ICER's ~$95,000 berotralstat fair-value anchor and, in England, to the confidential Patient Access Scheme net prices sitting behind NICE's standard cost-effectiveness bar. The same attacks-averted spine drives the GCC case, where averted laryngeal events justify NPHC individual-case submissions.
Positioning starts from the contested cohort, not head-to-head efficacy, because five of six agents cluster near the top of the efficacy band. AXLRx maps each entrant on the two axes that actually move share: route, injectable magnitude versus oral convenience, and mechanism, plasma-kallikrein, Factor XIIa or antisense. The strategy targets the never-prophylaxed pool, 2,500 to 4,000 in the US and 350 to 500 in the GCC, rather than switching stable patients. Comparator selection then becomes the HTA question: which incumbent a submission must beat, and how to infer a defensible net-price corridor from the few transparent list anchors when every recommended agent's net price stays confidential.
Every answer here is drawn from a connected AXLRx evidence base built for a specific brand decision. A Patient Flow Model isolates the never-prophylaxed cohort across the US, UK and GCC; a Competitive Intelligence read tracks the fracturing prophylaxis and on-demand class; a Disease Landscape sizes biology, attack burden and the diagnostic gap; a Payer and HTA analysis covers specialty-tier prior authorisation, NICE precedent and NPHC individual-case bars; KOL Mapping locates the concentrated specialist centres, five NHS sites and three GCC anchor institutions; and a Pricing Strategy Model reconciles $300,000-plus US costs with confidential UK net prices and GCC tender and VHI channels.